SCHEMBL29476448

SCHEMBL29476448

C[C@@H](NC(=O)[C@H](N)CCS)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 6/20 0.54
▸ IL23R Q5VWK5 1/20 0.52
▸ GHSR Q92847 2/20 0.51
▸ NPBWR1 P48145 2/20 0.51
▸ MC4R P32245 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29476589 1.00 KISS1R (0.54) KISS1RIL23RGHSRNPBWR1MC4R
SCHEMBL29476420 1.00 KISS1R (0.54) KISS1RIL23RGHSRNPBWR1MC4R
SCHEMBL30264784 0.96 KISS1R (0.55) KISS1RIL23RGHSRNPBWR1
SCHEMBL30264955 0.96 KISS1R (0.55) KISS1RIL23RGHSRNPBWR1
SCHEMBL30264852 0.96 KISS1R (0.55) KISS1RIL23RGHSRNPBWR1
SCHEMBL30264867 0.96 KISS1R (0.55) KISS1RIL23RGHSRNPBWR1
SCHEMBL30264819 0.96 KISS1R (0.55) KISS1RIL23RGHSRNPBWR1
SCHEMBL30264824 0.96 KISS1R (0.55) KISS1RIL23RGHSRNPBWR1
SCHEMBL29476439 0.96 KISS1R (0.55) KISS1RIL23RGHSRNPBWR1
SCHEMBL29476441 0.96 KISS1R (0.55) KISS1RIL23RGHSRNPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118271400-A Peptide composition 节奏制药公司 2024-07-02 — — CN claimed
CN-118240012-A Peptide composition 节奏制药公司 2024-06-25 — — CN claimed
US-20250188124-A1 PEPTIDE COMPOSITIONS RHYTHM PHARMACEUTICALS, INC. 2025-06-12 — — US disclosed
CN-105492456-B Peptide composition 节奏制药公司 2024-11-01 — — CN disclosed
US-12077612-B2 Peptide compositions RHYTHM PHARMACEUTICALS, INC. (US) 2024-09-03 — — US disclosed
CN-118271400-A Peptide composition 节奏制药公司 2024-07-02 — — CN disclosed
CN-118240012-A Peptide composition 节奏制药公司 2024-06-25 — — CN disclosed
EP-4216979-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS Rhythm Pharmaceuticals, Inc. (US) 2023-08-02 — — EP disclosed
CN-116507353-A Methods of treating melanocortin-4 receptor pathway-related disorders 节奏制药公司 2023-07-28 — — CN disclosed
CN-115957297-A Pharmaceutical composition 节奏制药公司 2023-04-14 — — CN disclosed
CN-115957296-A Pharmaceutical composition 节奏制药公司 2023-04-14 — — CN disclosed
WO-2022067086-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS RHYTHM PHARMACEUTICALS, INC. (US) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188124-A1 PEPTIDE COMPOSITIONS MC4R, MC3R, MC5R KISS1R 170/4885IL23R 473/4885GHSR 35/4885
US-12077612-B2 Peptide compositions MC4R, MC3R, MC5R KISS1R 170/4885IL23R 473/4885GHSR 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback